Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Executives from Recursion (Nasdaq: RXRX), a leading clinical stage TechBio ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In other recent news, Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, delivering results that surpassed expectations. The company posted an earnings per share (EPS) of -$0.21, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Great. Thanks, everyone, for joining. My name is Scott Schoenhaus. I am the health care tech equity analyst here at KeyBanc. We're a pleasure to have Ben Taylor, CFO of Recursion for a fireside chat.

Recursion (Nasdaq: RXRX) said on Wednesday that it had named Vicki Goodman as chief medical officer, effective April 6, 2026, succeeding David Mauro. Goodman had more than two decades of experience in ...

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor ...

Nvidia's recent $700 million acquisition of Run:ai enhances GPU access and infrastructure flexibility. The acquisition of OctoAI for $250 million bolsters Nvidia's generative AI tools portfolio.

The court accepted a case challenging an unusual investigation by Riverside County Sheriff Chad Bianco, who is running for California governor as a Republican. In Wisconsin, Harry Wait said he set out ...